| Literature DB >> 23236345 |
Lawrence Mbuagbaw1, Lehana Thabane, Pierre Ongolo-Zogo, Richard T Lester, Edward J Mills, Marek Smieja, Lisa Dolovich, Charles Kouanfack.
Abstract
BACKGROUND: Mobile phone technology is a novel way of delivering health care and improving health outcomes. This trial investigates the use of motivational mobile phone text messages (SMS) to improve adherence to antiretroviral therapy (ART) over six months. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2012 PMID: 23236345 PMCID: PMC3516507 DOI: 10.1371/journal.pone.0046909
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1CONSORT flow diagram for CAMPS trial.
Demographics and baseline.
| Variable | SMS group (n = 101) | Control group (n = 99) |
|
| 41.3 (10.1) | 39.0 (10.0) |
|
| ||
| Female | 69 (68.3) | 78 (78.8) |
|
| ||
| None | 1 (1.0) | 3 (3.0) |
| Primary | 42 (41.6) | 32 (32.3) |
| Secondary | 46 (45.5) | 51 (51.5) |
| Tertiary | 12 (11.9) | 13 (13.1) |
|
| 88 (87.1) | 92 (92.9) |
|
| 36 (35.6) | 26 (26.3) |
|
| 25.3 (4.1) | 25.2 (4.0) |
|
| 76 (75.2) | 70(70.7) |
|
| ||
| First line | 91 (90.1) | 88 (88.9) |
| Second line | 7 (6.9) | 11 (11.1) |
|
| 31.0 (15.0, 50.5) | 22.0 (7.0,46.0) |
|
| 347.0 (211.0, 527.5) | 327.0 (194.0,475.0) |
|
| 88.8 (13.42) | 92.4 (11.84) |
& = 1 missing;
β = 8 missing;
ε = 6 missing;
α = 3 missing;
δ = 4 missing;
μ = 2 missing;
SD: standard deviation; CDC: Centres for Disease Control, § CDC classifications: A3, B3, C1, C1, C3 [1]; CD4: CD4-positive-T-lymphocyte; Q1: first quartile; Q3: third quartile.
Outcomes at 6 months.
| Outcome | Type | SMS group (n = 101) | Control group (n = 99) | Effect Estimate |
|
|
|
|
|
|
| VAS>95% | 72 (71.3) | 66 (66.7) | 1.06 (0.89,1.29; 0.542 | |
| Self report (no missed doses) | 80 (79.2) | 78 (79.0) | 1.01 (0.87,1.16;) >0.999 | |
|
|
|
|
| |
| Pharmacy Refill Data | 3.8 (1.48) | 3.7 (1.34) | 0.1 (−0.23,0.43); 0.617 | |
|
|
|
|
|
|
| VAS>90% | 91 (90.1) | 78 (78.8) | 1.14 (1.01,1.29);0.027 | |
| Presence of a new OI | 20 (19.8) | 17 (17.2) | 1.15 (0.64,2.07); 0.632 | |
| Mortality | 3 (2.9) | 1(1.0) | 2.94 (0.31–27.79); 0.322 | |
| Retention | 80 (79.2) | 83 (83.8) | 0.95 (0.83,1.08); 0.399 | |
|
|
|
|
| |
| Weight (kg) | 71.8 (11.97) | 70.2 (11.87) | 1.60(−1.72,4.92); 0.344 | |
| BMI | 26.54 (4.254) | 25.73(3.823) | 0.81(−0.32,1.94); 0.159 | |
| Quality of life (SF-12 scale score) | 3.79 (0.585) | 3.75 (0.583) | 0.04(−0.12,0.20); 0.629 |
(SMS: short message service; RR: risk ratio; CI: confidence interval; SD: standard deviation; MD: mean difference; VAS: visual analogue scale; BMI: body mass index; OI: opportunistic infection; CD4: CD4-positive-T-lymphocyte; SF: short form).
Bonferroni adjustment for secondary outcomes: 0.05/8 = 0.006.
Insufficient data for CD4 count (n = 34 for intervention and 26 for control; MD-24.4; 95% CI: −101.3, 52.6; p = 0.599) and viral load (n = 0).
P-values obtained using the chi-squared test and the t-test for binary and continuous outcomes respectively.
Outcomes at 3 months.
| Outcome | Type | SMS group (n = 101) | Control group (n = 99) | Effect Estimate |
|
|
|
|
|
|
| VAS>95% | 52(51.5) | 66(66.7) | 0.77(0.63,0.94);0.029 | |
| Self report (no missed doses) | 82 (81.2) | 83(83.8) | 0.97(0.85,1.10);0.622 | |
|
|
|
|
| |
| Pharmacy Refill Data | 2.3(0.50) | 2.2 (0.45) | 0.10 (−0.03,0.23);0.139 | |
|
|
|
|
|
|
| VAS>90% | 60(59.4) | 70(70.7) | 0.61(0.32,1.14);0.094 | |
| Presence of a new OI | 39(38.6) | 32(32.3) | 1.19 (0.82,1.74);0.353 | |
| Mortality | 0 | 0 | Not estimable | |
| Retention | 85(84.2) | 84(84.8) | 0.99(0.88,1.12); 0.893 | |
|
|
|
|
| |
| Weight (kg) | 70.9(12.18) | 71.2(12.96) | −0.30 (−3.81,3.21);0.866 | |
| BMI | 26.24(4.087) | 26.07(4.175) | 0.17 (−0.98,1.32);0.771 | |
| CD4 (cells per mm3): | 406 (230) | 375 (225) | 31 (−32.5,94.5); 0.337 | |
| Quality of life (SF-12 scale score) | 3.67 (0.623) | 3.69 (0.615) | −0.20(−0.19,0.15);0.820 |
(SMS: short message service; RR: risk ratio; CI: confidence interval; SD: standard deviation; MD: mean difference; VAS: visual analogue scale; BMI: body mass index; OI: opportunistic infection; CD4: CD4-positive-T-lymphocyte; SF: short form).
Bonferroni adjustment for secondary outcomes: 0.05/8 = 0.006.
Insufficient data for viral load (n = 0).
P-values obtained using the chi-squared test and the t-test for binary and continuous outcomes respectively.
Satisfaction with the text message among the participants who received text messages (n = 101).
| Question | Count (%) |
|
| |
| Excellent | 12 (11.8) |
| Very good | 30 (29.7) |
| Good | 21(20.8) |
| Average | 17 (16.8) |
| Bad | 5 (4.9) |
| Very bad | 16 (15.8) |
|
| |
| Yes | 92 (91.1) |
| No | 9 (8.9 |
|
| |
| Yes | 66 (65.3) |
| No | 35 (34.7) |
|
| |
| Yes | 82 (81.2) |
| No | 19 (18.8) |
Percentages may not add up to 100 due to rounding off.